PRESS-RELEASE filed May 14, 2026 at 07:30 ET
CorMedix reported Q1 2026 revenue of $127.4M (21% above $105M consensus) and GAAP EPS of $0.43 diluted (30% above $0.33 consensus), driven by strong DefenCath sales ($97.5M) and the acquired Melinta portfolio ($29.9M). The company raised full-year 2026 revenue guidance to $325-345M and adjusted EBITDA guidance to $115-135M, while also announcing positive Phase III ReSPECT trial results for REZZAYO prophylaxis, supporting a bullish outlook.